SureNano Science's GEP-44 Targets Next-Generation GLP-1 Market with Triple Agonist Mechanism

SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) was featured in a NetworkNewsAudio editorial examining the evolution of the GLP-1 treatment market, highlighting the company’s development of GEP-44, a patented next-generation metabolic therapy designed to improve on first-generation GLP-1 drugs. The editorial noted GEP-44’s triple agonist mechanism targeting GLP-1 and peptide YY receptors, with preclinical data indicating potential benefits in appetite suppression, weight reduction and glycemic control with improved tolerability.

The GLP-1 drug market has experienced explosive growth, driven by the success of injectable therapies for diabetes and obesity. However, first-generation drugs often come with side effects such as nausea and vomiting, leading to patient discontinuation. GEP-44 aims to address these limitations through its unique triple agonist mechanism, which simultaneously targets GLP-1 and peptide YY receptors. Preclinical studies suggest this approach may enhance metabolic benefits while reducing gastrointestinal side effects, potentially improving patient adherence. Additionally, the therapy is being explored for non-injectable delivery routes, which could significantly expand its accessibility and patient acceptance.

SureNano Science has acquired GlucaPharm Inc., the company behind GEP-44, positioning itself as a player in the next wave of metabolic therapies. The acquisition, announced in a press release dated February 23, 2026, marks a strategic shift for SureNano from its initial business of distributing the SureNano surfactant—a food-grade compound for nanoemulsions—toward becoming a pharmaceutical-focused company. The company holds an exclusive license to distribute the surfactant in Canada, Oklahoma, and Colorado, but its future growth is increasingly tied to the development of GEP-44.

The obesity and metabolic disease market represents a significant opportunity, with global prevalence rising. GLP-1 therapies have become blockbuster drugs, but the need for improved tolerability and alternative delivery methods remains unmet. GEP-44’s preclinical profile suggests it could fill this gap, though clinical trials and regulatory approvals lie ahead. The company’s newsroom at https://nnw.fm/SURNF provides updates on its progress.

For investors, the development of GEP-44 underscores the potential for next-generation therapies to capture market share from existing drugs. However, risks include the early-stage nature of the therapy and the competitive landscape. The full press release detailing the editorial can be accessed at https://nnw.fm/wsiDy.